Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Late stage assay provider counterscreen for the probe development effort to identify IDE inhibitors: Fluorescence-based cysteine-free mutant IDE activity assay using a fluorogenic peptide substrate (FRET1) (reversibility)
Assay data:2 Active, 13 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
siRNA Circadian Assay
Assay data:527 Active, 33364 Tested
SummaryPubMed CitationRelated BioAssays by Depositor
Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE)
Assay data:1316 Active, 324858 Tested
Summary of probe development efforts to identify inhibitors of insulin-degrading enzyme (IDE)
SummaryPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
Fluorescence polarization-based cell-based high throughput confirmation assay for inhibitors of insulin-degrading enzyme (IDE)
Assay data:598 Active, 1179 Tested
Dose Response: Fluorescence polarization-based cell-based high throughput dose response assay for inhibitors of insulin-degrading enzyme (IDE)
Assay data:44 Active, 1 Activity ≤ 1 µM, 127 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE)
Assay data:245 Active, 335461 Tested
Summary of probe development efforts to identify activators of insulin-degrading enzyme (IDE)
Fluorescence polarization-based cell-based high throughput dose response assay to identify activators of insulin-degrading enzyme (IDE)
Assay data:32 Active, 1 Activity ≤ 1 µM, 231 Tested
Counterscreen for IDE activators: Fluorescence polarization-based biochemical high throughput dose response assay for activators of recombinant IDE
Assay data:18 Active, 231 Tested
Late stage counterscreen assay for the probe development effort to identify inhibitors of insulin-degrading enzyme (IDE): Fluorescence polarization-based biochemical dose response assay for inhibitors of recombinant IDE
Assay data:9 Active, 32 Tested
Late stage assay for the probe development effort to identify inhibitors of insulin-degrading enzyme (IDE): Fluorescence polarization-based cell-based dose response assay for inhibitors of IDE
Assay data:7 Active, 32 Tested
Late stage assay provider counterscreen assay for the probe development effort to identify activators of insulin-degrading enzyme (IDE): Fluorescence polarization-based biochemical dose-response assay for activators of wild-type (WT) recombinant IDE
Assay data:3 Tested
Late stage assay provider counterscreen for the probe development effort to identify IDE inhibitors: Fluorescence polarization-based biochemical dose-response assay for inhibitors of wild-type (WT) recombinant IDE
Assay data:6 Active, 8 Tested
An siRNA screen for human genes that are involved in human papilloma virus (HPV) E2 transcriptional repression of the E6 and E7 oncogenes
Assay data:497 Active, 21019 Tested
SummaryPubMed Citation
RNAi screen for vemurafenib enhancer genes in BRAFV600 melanoma - Primary Screen
Assay data:790 Active, 18119 Tested
Summary
Late stage assay provider counterscreen for the probe development effort to identify IDE inhibitors: Fluorescence-based cysteine-free mutant IDE activity assay using a fluorogenic peptide substrate (FRET1) (reversibility) (Round 2)
Assay data:26 Tested
Late stage assay provider counterscreen for the probe development effort to identify IDE inhibitors: Fluorescence polarization-based biochemical dose-response assay for inhibitors of wild-type (WT) recombinant IDE (ROUND 2)
Assay data:3 Active, 26 Tested
Genome-wide high-content siRNA screens for regulators of Parkin translocation in selective mitophagy (Dharmacon Library)
Assay data:826 Active, 18119 Tested
Genome-wide high-content siRNA screens for regulators of Parkin translocation in selective mitophagy (Ambion Library)
Assay data:9227 Active, 64752 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on